ENEM Consulting LLC is a life-sciences regulatory consulting firm focused on medical devices, IVDs, and combination products, providing regulatory, clinical, and quality system support. According to the website, its key figure, Nandini Murthy, has more than 20 years of experience in regulatory affairs, clinical work, and quality assurance. She has worked on a range of cardiovascular, neurological, imaging, diagnostic, and innovative device projects, with experience in FDA approvals and various submission documents.
Its services cover regulatory strategy, project planning, submission document writing and review, FDA communications, international registrations, clinical study design, clinical site audits, CRO/GLP audits, quality system development, and supplier audits. Submission types include PMA, IDE, 510(k), HDE, combination product IND/IDE, NDA/PMA, as well as pathways such as CE Mark, Health Canada, and Japan PMDA. On the quality system side, the site mentions support for standards including FDA QSR, ISO 13485, GCP, ISO 14155, GLP, 21 CFR Part 11, IEC 62304, and ISO 10993.
The website does not disclose packages, pricing, trials, or a free version, nor does it mention common SaaS capabilities such as a cloud platform, self-hosting, APIs, third-party integrations, or role-based collaboration. It should therefore be viewed more as project-based or consulting-based professional services rather than standard enterprise software. Before purchasing, prospects should use Contact Us to clarify scope, deliverables, fees, timelines, and communication processes.
Its strengths are a relatively complete service chain that can combine regulatory strategy, engineering and clinical deliverables, and quality system development, making it suitable for novel or complex Class II/Class III products. The founderβs background and FDA submission experience are the main sources of credibility. Limitations include only moderate transparency on the website, with a lack of customer case studies, team size, SLA details, data security certifications, and pricing information. It is not a good fit for companies looking for a ready-to-use SaaS platform.
It is better suited to medical device, IVD, and combination product companies preparing to enter the U.S. or international markets, especially early-stage innovators, financing/M&A due diligence scenarios, or teams that need support communicating with the FDA. The site does not state access conditions from China, and payment methods are also unknown. For Chinese companies mainly targeting NMPA registration, it is advisable to also evaluate local registration consultants, CROs, and quality system advisors as alternatives or complements.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on enemconsulting.com official site.
enemconsulting.com is an United States SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach enemconsulting.com directly.